Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00689780 | Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940 | PHASE1 | COMPLETED | 60 | — | — | Mar 1, 2008 | Nov 1, 2008 | Dec 10, 2010 | 3 | Sweden |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | AZD1940 + Placebo |
| 2 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| AZD1940 | DRUG | Oral solution Multiple ascending dose given orally once daily at day 1-12 |
| Midazolam | DRUG | Oral solution given orally once daily on day -1 and day 14 |
Inclusion Criteria: * A diagnosis of Chronic Low Back Pain according to Quebec Task force Class 1-3 and an average pain intensity score of 3-9 on NRS(0-10) during the past week. * Clinical normal physical findings, including blood pressure, pulse rate \> 45bpm, ECG (with normal QTcF interval \<450m...